Name | nNOS |
---|---|
Synonyms | Constitutive NOS; NOS1; IHPS 1; IHPS1; N NOS; NC NOS; NOS; NOS type I… |
Name | piperazine |
---|---|
CAS | piperazine |
PubMed | Abstract | RScore(About this table) | |
---|---|---|---|
20164327 | Zhang J, Huang XY, Ye ML, Luo CX, Wu HY, Hu Y, Zhou QG, Wu DL, Zhu LJ, Zhu DY: Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J Neurosci. 2010 Feb 17;30(7):2433-41. Here, we show that 5-HT (1A) R-selective agonist 8-OH-DPAT and selective reuptake inhibitor (SSRI) fluoxetine downregulated hippocampal neuronal synthase (nNOS) expression, whereas 5-HT (1A) R-selective antagonist NAN-190 upregulated hippocampal nNOS expression. |
3(0,0,0,3) | Details |
19799710 | Park DJ, West AR: Regulation of striatal synthesis by local and interactions. J Neurochem. 2009 Dec;111(6):1457-65. Epub 2009 Oct 3. To study the impact of local manipulations of D1/5 and glutamatergic NMDA receptors on striatal nNOS activity, we combined the techniques of in vivo amperometry and reverse microdialysis. NO efflux elicited by systemic administration of SKF-81297 was blocked following intrastriatal infusion of: (i) the D1/5 receptor antagonist SCH-23390, (ii) the nNOS inhibitor 7-nitroindazole, (iii) the non-specific ionotropic glutamate receptor antagonist and (iv) the selective NMDA receptor antagonist 3-phosphonopropyl-piperazine-2-carboxylic acid. |
3(0,0,0,3) | Details |
12606778 | Habisch HJ, Gorren AC, Liang H, Venema RC, Parkinson JF, Schmidt K, Mayer B: Pharmacological interference with dimerization of human neuronal A recombinant adenovirus containing the cDNA of human neuronal synthase (nNOS) was constructed to characterize the interaction of nNOS with N-[(1,3-benzodioxol-5-yl) methyl]-1-[2- -1-yl) pyrimidin-4-yl]-4 -(methoxycarbonyl)-piperazine-2-acetamide (BBS-1), a potent inhibitor of inducible NOS dimerization [Proc Natl Acad Sci USA 97:1506-1511, 2000]. |
synthase expressed in adenovirus-infected DLD-1 cells. Mol Pharmacol. 2003 Mar;63(3):682-9.35(0,1,1,5) | Details |